Cochrane · systematic review · CD012804
Anti‐IL‐12/23p40 antibodies for maintenance of remission in Crohn's disease
Davies, SC, Nguyen, TM, Parker, CE, et al. · Cochrane Database of Systematic Reviews · 2019 · Cochrane Library
GutAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
12
current version
GRADE rated
12
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 6 · 50%Moderate 5 · 41.7%High 1 · 8.3%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Ustekinumab compared to placebo for maintenance of remission in Crohn's disease
Population: people with moderate to severe Crohn's disease in remission
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Failure to maintain clinical remission Ustekinumab vs placebo | RR 0.8 [0.63, 1.02] | 1 study · 145 participants | Moderate Downgraded: imprecision |
Failure to maintain clinical response Ustekinumab vs placebo | RR 0.53 [0.36, 0.79] | 1 study · 145 participants | Moderate Downgraded: imprecision |
Failure to maintain clinical remission Ustekinumab vs placebo | RR 0.76 [0.64, 0.91] | 1 study · 388 participants | Moderate Downgraded: imprecision |
Failure to maintain clinical response Ustekinumab vs placebo | RR 0.74 [0.6, 0.91] | 1 study · 388 participants | Moderate Downgraded: imprecision |
Adverse events Ustekinumab vs placebo | RR 0.94 [0.87, 1.03] | 2 studies · 541 participants | High |
Serious adverse events Ustekinumab vs placebo | RR 0.74 [0.48, 1.15] | 2 studies · 541 participants | Moderate Downgraded: imprecision |
Withdrawal due to adverse events Ustekinumab vs placebo | RR 4.93 [0.59, 41.18] | 1 study · 145 participants | Low Downgraded: imprecision |
Briakinumab compared to placebo for maintenance of remission in Crohn's disease
Population: people with moderate to severe Crohn's disease in remission
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Failure to maintain clinical remission Briakinumab vs placebo | RR 0.84 [0.58, 1.2] | 1 study · 99 participants | Low Downgraded: imprecision |
Failure to maintain clinical response Briakinumab vs placebo | RR 0.64 [0.4, 1.02] | 1 study · 99 participants | Low Downgraded: imprecision |
Adverse events Briakinumab vs placebo | RR 1.02 [0.67, 1.55] | 1 study · 104 participants | Low Downgraded: imprecision |
Serious adverse events Briakinumab vs placebo | RR 0.31 [0.03, 3.21] | 1 study · 104 participants | Low Downgraded: imprecision |
Withdrawals due to adverse events Briakinumab vs placebo | RR 0.82 [0.04, 16.34] | 1 study · 104 participants | Low Downgraded: imprecision |